iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Moderate Buy” by Analysts

iRadimed Corporation (NASDAQ:IRMD) has received an average rating of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $87.3333.

A number of research analysts have issued reports on IRMD shares. Roth Capital set a $90.00 price objective on shares of iRadimed in a research report on Friday, October 31st. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Weiss Ratings reiterated a “buy (b)” rating on shares of iRadimed in a report on Friday, October 31st. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Finally, Zacks Research raised shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th.

iRadimed Stock Performance

IRMD stock opened at $92.95 on Monday. The firm has a market cap of $1.18 billion, a P/E ratio of 57.38 and a beta of 1.04. iRadimed has a 52 week low of $47.48 and a 52 week high of $93.43. The firm’s fifty day moving average is $79.28 and its 200 day moving average is $68.76.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. The business had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.50 million. iRadimed had a return on equity of 23.30% and a net margin of 26.61%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS. FY 2025 guidance at 1.840-1.880 EPS. As a group, analysts forecast that iRadimed will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, November 25th. Investors of record on Friday, November 14th were issued a $0.17 dividend. The ex-dividend date was Friday, November 14th. This represents a $0.68 annualized dividend and a yield of 0.7%. iRadimed’s dividend payout ratio (DPR) is currently 41.21%.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $90.36, for a total transaction of $451,800.00. Following the completion of the sale, the chief executive officer directly owned 2,307,500 shares in the company, valued at approximately $208,505,700. The trade was a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 50,000 shares of company stock valued at $3,840,650. Insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

Several large investors have recently modified their holdings of the company. CWM LLC lifted its holdings in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the period. Quarry LP bought a new position in shares of iRadimed in the 3rd quarter worth approximately $40,000. Tower Research Capital LLC TRC lifted its stake in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of iRadimed in the third quarter worth approximately $47,000. Finally, Spire Wealth Management bought a new stake in iRadimed during the second quarter valued at approximately $60,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.